Climb Bio Q3 2024 Earnings Report

Climb Bio EPS Results

• Actual EPS: -$0.13
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Climb Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Climb Bio Announcement Details

• Quarter: Q3 2024
• Date: 11/12/2024
• Time: After Market Closes
• Conference Call Date: Tuesday, November 12, 2024
• Conference Call Time: 9:30AM ET

Climb Bio (NASDAQ:CLYM) is a clinical-stage biotechnology company focused on the discovery and development of targeted protein degraders for the treatment of cancer and other serious diseases. The company is leveraging an integrated drug discovery platform that combines medicinal chemistry, structural biology and proprietary assays to identify small molecules capable of directing disease-causing proteins to the cell’s natural degradation machinery. With a primary emphasis on oncology, Climb Bio’s lead programs are designed to address high-unmet-need targets that have historically proven difficult to modulate with traditional small-molecule inhibitors or biologics.

Since its formation as an independent public company, Climb Bio has built a pipeline that spans multiple therapeutic modalities and target classes. Its research and development efforts are supported by state-of-the-art laboratories in the United States, where multidisciplinary teams work on early-stage discovery as well as translational research. The company has also established strategic partnerships to broaden its scientific capabilities and expedite the advancement of its most promising candidates toward clinical evaluation. Through these collaborations, Climb Bio aims to capitalize on external expertise while retaining core control over its proprietary chemistry and screening platforms.

Climb Bio was founded by a group of industry veterans and academic scientists with deep experience in drug discovery, structural biology and oncology. The senior management team includes executives who have previously led successful biotech ventures and overseen late-stage clinical programs. Based in the U.S., with outreach to select research centers in Europe and Asia, the company combines global scientific collaboration with a nimble organizational structure. This approach is intended to streamline decision-making and foster rapid progress from target discovery through clinical development.